Immatics Announces Q3 2025 Financial Results & Update
Immatics has moved its PRAME franchise into a pivotal phase, with a global, randomized Phase 3 trial (SUPRAME) of...
No videos found.
Avadel Board: Lundbeck’s Bid a “Company Superior Proposal”
Avadel’s board has deemed H. Lundbeck’s unsolicited bid to acquire the company a superior proposal to its existing deal...
Nxera’s Focused Restructuring to Enhance Path to Profit
Nxera Pharma will streamline its operations and refocus R&D around de-risked GPCR biology, cutting approximately 15% of its workforce...
James M. O’Brien Appointed as Mesoblast Chief Financial Officer
Mesoblast has appointed James M. O’Brien as its US-based chief financial officer as the company transitions to a fully...
Fennec Pharmaceuticals Q3 2025 Financial Results Update
Fennec Pharmaceuticals reported record third-quarter 2025 net product sales of $12.5 million for Pedmark, up 79% year over year,...
Predictive Oncology Q3 Results & New Digital Asset Strategy
Predictive Oncology has launched an aggressive pivot into decentralized AI infrastructure alongside reporting weak third-quarter financials. The company initiated...
Benitec Biopharma Releases Q1 2026 Financials, Ops Update
Benitec Biopharma has secured FDA Fast Track designation for BB-301 and reported positive interim results from its Phase 1b/2a...
HCW Biologics Reports Third Quarter 2025 Financial Results
HCW Biologics reported third-quarter 2025 results and outlined near-term clinical milestones, including plans to dose the first patient in...
Mesoblast Appoints James M. O’Brien Chief Financial Officer
Mesoblast has appointed James M. O’Brien as its US-based chief financial officer, aligning the company’s finance leadership with its...
Verrica Pharmaceuticals Reports Q3 2025 Financial Results
Verrica Pharmaceuticals reported third-quarter 2025 revenue of $14.3 million, driven by $3.6 million in Ycanth sales and $10.7 million...